Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2025
0mins
Should l Buy HIMS?
Source: NASDAQ.COM
Hims & Hers Health Performance: Hims & Hers stock surged 11.2% after reporting a sales beat with a 111% year-over-year increase, despite an earnings miss of $0.20 per share compared to the expected $0.23. The company forecasts continued growth, projecting sales between $2.3 billion and $2.4 billion for the year.
Impact on Competitors: The positive outlook for Hims & Hers is seen as a competitive threat to larger drugmakers like Eli Lilly and Novo Nordisk, whose stocks fell by 3.2% following the news, indicating concerns about sharing future profits in the GLP-1 market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 21.340
Low
16.50
Averages
32.95
High
60.00
Current: 21.340
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Partners with Novo Nordisk for Wegovy Launch
- Partnership Outlook: Hims & Hers has entered into an agreement with Novo Nordisk to launch the Wegovy pill, which is expected to provide new growth momentum for the company, particularly in the latter half of 2026, potentially improving its operational status significantly.
- Market Potential: The strong demand for Wegovy as a weight-loss medication could position Hims & Hers as a high-growth stock, attracting more investor interest and enhancing the overall valuation of the company.
- Strategic Significance: This partnership not only introduces a new product line for Hims & Hers but may also enhance its market position in the health and beauty sector, further driving brand recognition and expanding its customer base.
- Future Outlook: With the launch of Wegovy, Hims & Hers is poised to achieve significant sales growth by the end of 2026, further solidifying its position in the competitive health product market.
See More
Novo Nordisk and Hims & Hers Deal Sparks New Product Launches
- Product Launch Outlook: The collaboration between Hims & Hers and Novo Nordisk will introduce the Wegovy pill, expected to be the fastest GLP-1 launch in history, potentially driving significant growth for the company in 2026.
- Market Recovery Potential: Despite facing challenges in 2026, the deal with Novo Nordisk is poised to revitalize Hims & Hers' operations, enhancing the company's market performance in the coming years.
- Distribution Channel Expansion: The new agreement will broaden Hims & Hers' distribution channels, enabling more effective outreach to target customers, thereby boosting sales and market share.
- Investor Interest: With the upcoming product launch, Hims & Hers could emerge as a high-growth stock, attracting investor attention and increasing its market valuation.
See More
Hims & Hers Health, Inc. Under Investigation Following Legal Issues
- Investigation Launched: Kahn Swick & Foti, LLC has initiated an investigation into Hims & Hers Health, Inc., focusing on whether its executives breached fiduciary duties to shareholders, which could impact corporate governance.
- Partnership Termination Impact: Novo Nordisk announced the termination of its partnership with Hims in June 2025, citing the company's failure to comply with laws, potentially jeopardizing patient safety and severely damaging its market reputation.
- Securities Lawsuit Progress: Hims & Hers and its executives are facing a securities class action lawsuit for failing to disclose material information, with the court denying the company's motion to dismiss, allowing the case to proceed and potentially resulting in significant financial liabilities.
- Investor Rights at Risk: KSF is urging long-term holders of Hims shares to provide information, indicating that the legal issues facing the company could significantly affect investor rights and increase investment risks.
See More
Novo Nordisk Shares Plummet Amidst Dismal Guidance
- Stock Price Decline: Novo Nordisk's shares have plummeted over 50% in the past year, reaching their lowest levels since early 2021, indicating investor dissatisfaction with recent performance and a pessimistic outlook for the future.
- Guidance Downgrade: The company projects a potential revenue decline of up to 13% for the current year, and despite launching a new Wegovy pill, pricing pressures have raised doubts about its growth potential, which could impact investor confidence moving forward.
- Strategic Partnership: Novo Nordisk has partnered with telehealth company Hims & Hers Health to sell its GLP-1 products on Hims' platform, a move that could drive sales growth and improve performance amid current challenges.
- Investment Opportunity: Despite facing short-term headwinds, Novo Nordisk's stock trades at just 10 times earnings, suggesting it is undervalued, and long-term investors may find an attractive entry point at this low price, especially if market sentiment improves.
See More
Novo Nordisk Issues Troubling 2026 Guidance, Stock Plummets
- Stock Plunge: Novo Nordisk's stock has lost over 50% of its value in the past 12 months, trading at just 10 times earnings, reflecting extreme market pessimism regarding its future performance and severely undermining investor confidence.
- 2026 Guidance Cut: The company projects a revenue decline of up to 13% for the current year, despite launching a new Wegovy pill, as management faces pricing pressures and must lower prices to attract customers and gain market share, impacting future growth potential.
- Partnership with Hims & Hers: Novo Nordisk has reached an agreement with telehealth company Hims & Hers to sell its GLP-1 products on their platform, which could provide new momentum for sales growth following the release of its troubling guidance, potentially improving performance.
- Long-term Investment Opportunity: Despite current challenges, Novo Nordisk's low valuation offers a good margin of safety for long-term investors; renowned investor Warren Buffett has noted his preference for investing in companies facing
See More
Hims & Hers Launches Waitlist for Ozempic and Wegovy
- Partnership Announcement: Hims & Hers Health Inc. has partnered with Novo Nordisk AS to launch a pre-launch waitlist for Ozempic and Wegovy, indicating a strategic move into the prescription drug market that could enhance its competitive edge in health technology.
- Priority Access: Users who sign up for the waitlist will gain priority access to the official launch of Ozempic and Wegovy, which not only improves user experience but may also attract more customers to Hims & Hers' telehealth services, potentially driving revenue growth.
- Market Reaction: Despite Hims & Hers shares declining nearly 1% in pre-market trading on Wednesday, retail sentiment on Stocktwits trended bullish, suggesting that investor confidence in the company's future prospects remains strong, which could influence subsequent stock performance.
- User Engagement: By encouraging user participation through high message volumes on social media platforms during the waitlist launch, Hims & Hers not only enhances its market presence but may also foster customer loyalty and engagement.
See More
Hims & Hers Partners with Novo Nordisk for Wegovy Launch
- Partnership Outlook: Hims & Hers has entered into an agreement with Novo Nordisk to launch the Wegovy pill, which is expected to provide new growth momentum for the company, particularly in the latter half of 2026, potentially improving its operational status significantly.
- Market Potential: The strong demand for Wegovy as a weight-loss medication could position Hims & Hers as a high-growth stock, attracting more investor interest and enhancing the overall valuation of the company.
- Strategic Significance: This partnership not only introduces a new product line for Hims & Hers but may also enhance its market position in the health and beauty sector, further driving brand recognition and expanding its customer base.
- Future Outlook: With the launch of Wegovy, Hims & Hers is poised to achieve significant sales growth by the end of 2026, further solidifying its position in the competitive health product market.
See More
Novo Nordisk and Hims & Hers Deal Sparks New Product Launches
- Product Launch Outlook: The collaboration between Hims & Hers and Novo Nordisk will introduce the Wegovy pill, expected to be the fastest GLP-1 launch in history, potentially driving significant growth for the company in 2026.
- Market Recovery Potential: Despite facing challenges in 2026, the deal with Novo Nordisk is poised to revitalize Hims & Hers' operations, enhancing the company's market performance in the coming years.
- Distribution Channel Expansion: The new agreement will broaden Hims & Hers' distribution channels, enabling more effective outreach to target customers, thereby boosting sales and market share.
- Investor Interest: With the upcoming product launch, Hims & Hers could emerge as a high-growth stock, attracting investor attention and increasing its market valuation.
See More
Hims & Hers Health, Inc. Under Investigation Following Legal Issues
- Investigation Launched: Kahn Swick & Foti, LLC has initiated an investigation into Hims & Hers Health, Inc., focusing on whether its executives breached fiduciary duties to shareholders, which could impact corporate governance.
- Partnership Termination Impact: Novo Nordisk announced the termination of its partnership with Hims in June 2025, citing the company's failure to comply with laws, potentially jeopardizing patient safety and severely damaging its market reputation.
- Securities Lawsuit Progress: Hims & Hers and its executives are facing a securities class action lawsuit for failing to disclose material information, with the court denying the company's motion to dismiss, allowing the case to proceed and potentially resulting in significant financial liabilities.
- Investor Rights at Risk: KSF is urging long-term holders of Hims shares to provide information, indicating that the legal issues facing the company could significantly affect investor rights and increase investment risks.
See More
Novo Nordisk Shares Plummet Amidst Dismal Guidance
- Stock Price Decline: Novo Nordisk's shares have plummeted over 50% in the past year, reaching their lowest levels since early 2021, indicating investor dissatisfaction with recent performance and a pessimistic outlook for the future.
- Guidance Downgrade: The company projects a potential revenue decline of up to 13% for the current year, and despite launching a new Wegovy pill, pricing pressures have raised doubts about its growth potential, which could impact investor confidence moving forward.
- Strategic Partnership: Novo Nordisk has partnered with telehealth company Hims & Hers Health to sell its GLP-1 products on Hims' platform, a move that could drive sales growth and improve performance amid current challenges.
- Investment Opportunity: Despite facing short-term headwinds, Novo Nordisk's stock trades at just 10 times earnings, suggesting it is undervalued, and long-term investors may find an attractive entry point at this low price, especially if market sentiment improves.
See More
Novo Nordisk Issues Troubling 2026 Guidance, Stock Plummets
- Stock Plunge: Novo Nordisk's stock has lost over 50% of its value in the past 12 months, trading at just 10 times earnings, reflecting extreme market pessimism regarding its future performance and severely undermining investor confidence.
- 2026 Guidance Cut: The company projects a revenue decline of up to 13% for the current year, despite launching a new Wegovy pill, as management faces pricing pressures and must lower prices to attract customers and gain market share, impacting future growth potential.
- Partnership with Hims & Hers: Novo Nordisk has reached an agreement with telehealth company Hims & Hers to sell its GLP-1 products on their platform, which could provide new momentum for sales growth following the release of its troubling guidance, potentially improving performance.
- Long-term Investment Opportunity: Despite current challenges, Novo Nordisk's low valuation offers a good margin of safety for long-term investors; renowned investor Warren Buffett has noted his preference for investing in companies facing
See More
Hims & Hers Launches Waitlist for Ozempic and Wegovy
- Partnership Announcement: Hims & Hers Health Inc. has partnered with Novo Nordisk AS to launch a pre-launch waitlist for Ozempic and Wegovy, indicating a strategic move into the prescription drug market that could enhance its competitive edge in health technology.
- Priority Access: Users who sign up for the waitlist will gain priority access to the official launch of Ozempic and Wegovy, which not only improves user experience but may also attract more customers to Hims & Hers' telehealth services, potentially driving revenue growth.
- Market Reaction: Despite Hims & Hers shares declining nearly 1% in pre-market trading on Wednesday, retail sentiment on Stocktwits trended bullish, suggesting that investor confidence in the company's future prospects remains strong, which could influence subsequent stock performance.
- User Engagement: By encouraging user participation through high message volumes on social media platforms during the waitlist launch, Hims & Hers not only enhances its market presence but may also foster customer loyalty and engagement.
See More
